Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 4:23 AM
Ignite Modification Date:
2025-12-26 @ 3:25 AM
NCT ID:
NCT02938520
Group ID:
EG000
Title:
CAB LA+RPV LA (Q4W)
Description:
Participants who received ABC/DTG/3TC for 20 Weeks (Week \[-20\] to Day 1) in the Induction Phase and who have an HIV-1 ribonucleic acid (RNA) \<50 copies per millilter (c/mL) at Week (-4) entered Maintenance Phase (Day 1 to Week 100) to begin oral therapy with CAB 30 milligram (mg) + RPV 25 mg once daily for 4 Weeks. At Week 4b visit, participants received last dose of oral CAB + RPV and first dose CAB LA 600 mg + RPV LA 900 mg injections. Participants received intramuscular (IM) injections of CAB LA 400 mg and RPV LA 600 mg at Week 8 and every four weeks (Q4W) through Week 100. After completion of Maintenance Phase, participants who chose to enter Extension Phase will continue to receive both CAB LA and RPV LA. Participants withdrawn from study treatment who received at least one CAB LA+RPV LA injection were required to enter a 52-week long term follow-up period.
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
18
Serious Number At Risk:
283
Other Number Affected:
252
Other Number At Risk:
283
Study:
NCT02938520
Results Section:
NCT02938520
Adverse Events Module:
NCT02938520